About Us

SVMPharma is an innovative strategic consultancy, specialising in Real World Evidence (RWE) for the pharmaceutical industry.

SVMPharma generates RWE within UK and Europe through bespoke online Real World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets.

SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand. 

SVMPharma also provides Global RWE, Patient Real World Outcomes, and Big Data Analytics.

Staff

download  Vaneet Nayar 
      Director

download  Harrison Davis 
      Lead Medical Writer

download  Corwin Leung 
      Marketing and Sales Associate

SVMPHARMA UK LIMITED is part of SOLVERMINDS SOLUTIONS AND TECHNOLOGIES, a global product development and technology company specialising in enterprise application and analytics solutions. Since its inception in September 2003, the company has been at the forefront of delivering innovative solutions to customers.

With a team of 300+ developers, testers and project managers based in India, Malaysia, Denmark and United Kingdom, its team can provide global coverage to its clients.  The applications developed by SOLVERMINDS are used in 80+ countries.

More Information

 

Our Clients

AstraZeneca_logo_logotype

   Gilead-Logocolor-lg

  NAPP_logo   

ipsen-logo

    CELG

alimera_logo_color

       Cell Therapeutics Inc CTI BioPharma Corp Logo

   ALK_Log

Qunitiles

2016 Events

Meet SVMPharma at: 

JAN 29
30th Annual PM Society Awards London

MAY 10-11th
eyeforpharma Market Access & Real World Evidence EU Summit 2016  Amsterdam

2015 Events

Meet SVMPharma at: 

JAN 30
29th Annual PM Society Awards London

MAR 11
Inaugural SVMPharma and talkhealth RWE PCOS Seminar London

JUN 3-4
3rd Annual Real World Evidence Europe 2015 by eyeforpharma Amsterdam

JUN 11-14
20th Congress of the European Hematology Association (EHA) Vienna

NOV 7-11
ISPOR 18th Annual European Congress Milan

Publications and Presentations

Plant BJ, Downey D, Eustace JA, Gunaratnam C, Haworth C, Jones A, McKone, Peckham D, Ketchell I, and Bilton D. Inhaled aztreonam lysine (Cayston) therapy significantly improves lung function, weight, hospitalisations and exacerbation rates prospectively–an Irish and UK real world experience. 37th European Cystic Fibrosis Congress, Gothenburg 11-14 June 2014 Link

Dickerson S, Bantel C, and Mehta V. Fixed-Dose Combination Oxycodone/ Naloxone Reduces Constipation, Improves Quality of Life and Reduces Laxative Use: Real World Evidence from the Targinact® Treatment Evaluator (TTE). British Pain Society ASM 21-23 April 2015 Link

Cornford P, Jefferson K, Cole O, Gilbody JS, Nayar V and Auddy G. Switching to a 6-monthly triptorelin formulation for prostate cancer (PCa) reduces patient–NHS interactions and hospital resource use: Real World Evidence (RWE) from Project DESERVE (DEcapeptyl SERVice Evaluation). ISPOR 18th Annual European Congress, Milan 7-11 November 2015 Link

Horsley W, Nayar V, and Auddy G. Natalizumab use in multiple sclerosis: a Real World Evidence (RWE) analysis of its impact on NHS resources in England. ISPOR 18th Annual European Congress, Milan 7-11 November 2015 Link